Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adcetris in Steroid-Resistant Acute GVHD
NCT01616680Phase 2Withdrawn
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2012
- Primary completion
- Jun 2016
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in Acute Graft-Versus-Host Disease (aGVHD), sponsored by Fred Hutchinson Cancer Center. Planned start Sep 2012; status: withdrawn.
02
Drugs
brentuximab vedotin
03
Conditions
Acute Graft-Versus-Host Disease (aGVHD)
Beyond the preview
Go deeper on NCT01616680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01616680.